113 related articles for article (PubMed ID: 7614470)
1. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
[TBL] [Abstract][Full Text] [Related]
2. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
[TBL] [Abstract][Full Text] [Related]
4. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
Kisor DF
Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
[TBL] [Abstract][Full Text] [Related]
5. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
Verhoef V; Fridland A
Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
[TBL] [Abstract][Full Text] [Related]
6. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Gandhi V; Plunkett W; Rodriguez CO; Nowak BJ; Du M; Ayres M; Kisor DF; Mitchell BS; Kurtzberg J; Keating MJ
J Clin Oncol; 1998 Nov; 16(11):3607-15. PubMed ID: 9817282
[TBL] [Abstract][Full Text] [Related]
7. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
Rodriguez CO; Mitchell BS; Ayres M; Eriksson S; Gandhi V
Cancer Res; 2002 Jun; 62(11):3100-5. PubMed ID: 12036920
[TBL] [Abstract][Full Text] [Related]
8. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
10. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Aguayo A; Cortes JE; Kantarjian HM; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating MJ
Cancer; 1999 Jan; 85(1):58-64. PubMed ID: 9921974
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
12. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
[TBL] [Abstract][Full Text] [Related]
13. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells.
Shewach DS; Mitchell BS
Cancer Res; 1989 Dec; 49(23):6498-502. PubMed ID: 2819707
[TBL] [Abstract][Full Text] [Related]
14. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors.
Richardson F; Black C; Richardson K; Franks A; Wells E; Karimi S; Sennello G; Hart K; Meyer D; Emerson D; Brown E; LeRay J; Nilsson C; Tomkinson B; Bendele R
Cancer Chemother Pharmacol; 2005 Mar; 55(3):213-21. PubMed ID: 15592840
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
[TBL] [Abstract][Full Text] [Related]
17. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.
Rodriguez CO; Gandhi V
Cancer Res; 1999 Oct; 59(19):4937-43. PubMed ID: 10519407
[TBL] [Abstract][Full Text] [Related]
18. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
[TBL] [Abstract][Full Text] [Related]
19. Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.
Majlessipour F; Kwock R; Martin-Aragon S; Weinberg KI; Avramis VI
Anticancer Res; 2001; 21(1A):11-22. PubMed ID: 11299723
[TBL] [Abstract][Full Text] [Related]
20. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity.
Lotfi K; MÃ¥nsson E; Peterson C; Eriksson S; Albertioni F
Biochem Biophys Res Commun; 2002 May; 293(5):1489-96. PubMed ID: 12054684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]